Physician profile
David Green
NPI 1164607974
$1,381.75
in general payments reported to CMS, 2019-2025
24 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.57 · 2021: $21.28 · 2022: $430 · 2023: $332 · 2024: $155 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $282.27 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $168.15 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.06 | 2022-2025 | Ofev |
| Insmed, INC. | $113.78 | 2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $96.14 | 2022-2024 | Yupelri |
| Gilead Sciences, INC. | $72.56 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $67.66 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Inspire Medical Systems, INC. | $56.65 | 2023 | Inspire |
| Baxter Healthcare | $40.85 | 2022-2024 | Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $39.86 | 2022 | |
| Coaptech, INC. | $32.88 | 2025 | Puma System |
| Ambu INC. | $29.71 | 2024 | |
| Harmony Biosciences LLC | $27.34 | 2022 | |
| Inari Medical, INC. | $26.50 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Regeneron Healthcare Solutions, INC. | $22.10 | 2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.32 | 2022 | |
| Seagen INC. | $21.28 | 2021 | |
| Merck Sharp & Dohme LLC | $19.72 | 2020 | |
| La Jolla Pharmaceutical Company | $19.12 | 2023 | Giapreza |
| Abbvie INC. | $17.93 | 2024 | |
| United Therapeutics Corporation | $17.45 | 2023 | Remodulin |
| Olympus America INC. | $16.95 | 2022 | |
| Pfizer INC. | $16.85 | 2020 | |
| Resmed Corp | $14.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.